Advances in CD30- and PD-1-targeted therapies for classical Hodgkin lymphoma

Yucai Wang, Grzegorz S Nowakowski, Michael L. Wang, Stephen Maxted Ansell

Research output: Contribution to journalReview article

3 Citations (Scopus)

Abstract

CD30 and programmed cell death protein 1 (PD-1) are two ideal therapeutic targets in classical Hodgkin lymphoma (cHL). The CD30 antibody-drug conjugate (ADC) brentuximab vedotin and the PD-1 antibodies nivolumab and pembrolizumab are highly efficacious in treating relapsed and/or refractory cHL. Ongoing studies are evaluating their efficacy in earlier lines of therapy and have demonstrated encouraging results. These agents are expected to further change the landscape of cHL management. Increased cure rates and reduced long-term toxicity from traditional chemotherapy and radiotherapy are likely with the emergence of these novel targeted therapies.

Original languageEnglish (US)
Article number57
JournalJournal of Hematology and Oncology
Volume11
Issue number1
DOIs
StatePublished - Apr 23 2018

Fingerprint

Hodgkin Disease
Programmed Cell Death 1 Receptor
Antibodies
Secondary Prevention
Radiotherapy
Therapeutics
Drug Therapy
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Hematology
  • Molecular Biology
  • Oncology
  • Cancer Research

Cite this

Advances in CD30- and PD-1-targeted therapies for classical Hodgkin lymphoma. / Wang, Yucai; Nowakowski, Grzegorz S; Wang, Michael L.; Ansell, Stephen Maxted.

In: Journal of Hematology and Oncology, Vol. 11, No. 1, 57, 23.04.2018.

Research output: Contribution to journalReview article

@article{62444716f9ef44c4a88b8eec65982d29,
title = "Advances in CD30- and PD-1-targeted therapies for classical Hodgkin lymphoma",
abstract = "CD30 and programmed cell death protein 1 (PD-1) are two ideal therapeutic targets in classical Hodgkin lymphoma (cHL). The CD30 antibody-drug conjugate (ADC) brentuximab vedotin and the PD-1 antibodies nivolumab and pembrolizumab are highly efficacious in treating relapsed and/or refractory cHL. Ongoing studies are evaluating their efficacy in earlier lines of therapy and have demonstrated encouraging results. These agents are expected to further change the landscape of cHL management. Increased cure rates and reduced long-term toxicity from traditional chemotherapy and radiotherapy are likely with the emergence of these novel targeted therapies.",
author = "Yucai Wang and Nowakowski, {Grzegorz S} and Wang, {Michael L.} and Ansell, {Stephen Maxted}",
year = "2018",
month = "4",
day = "23",
doi = "10.1186/s13045-018-0601-9",
language = "English (US)",
volume = "11",
journal = "Journal of Hematology and Oncology",
issn = "1756-8722",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Advances in CD30- and PD-1-targeted therapies for classical Hodgkin lymphoma

AU - Wang, Yucai

AU - Nowakowski, Grzegorz S

AU - Wang, Michael L.

AU - Ansell, Stephen Maxted

PY - 2018/4/23

Y1 - 2018/4/23

N2 - CD30 and programmed cell death protein 1 (PD-1) are two ideal therapeutic targets in classical Hodgkin lymphoma (cHL). The CD30 antibody-drug conjugate (ADC) brentuximab vedotin and the PD-1 antibodies nivolumab and pembrolizumab are highly efficacious in treating relapsed and/or refractory cHL. Ongoing studies are evaluating their efficacy in earlier lines of therapy and have demonstrated encouraging results. These agents are expected to further change the landscape of cHL management. Increased cure rates and reduced long-term toxicity from traditional chemotherapy and radiotherapy are likely with the emergence of these novel targeted therapies.

AB - CD30 and programmed cell death protein 1 (PD-1) are two ideal therapeutic targets in classical Hodgkin lymphoma (cHL). The CD30 antibody-drug conjugate (ADC) brentuximab vedotin and the PD-1 antibodies nivolumab and pembrolizumab are highly efficacious in treating relapsed and/or refractory cHL. Ongoing studies are evaluating their efficacy in earlier lines of therapy and have demonstrated encouraging results. These agents are expected to further change the landscape of cHL management. Increased cure rates and reduced long-term toxicity from traditional chemotherapy and radiotherapy are likely with the emergence of these novel targeted therapies.

UR - http://www.scopus.com/inward/record.url?scp=85045922333&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85045922333&partnerID=8YFLogxK

U2 - 10.1186/s13045-018-0601-9

DO - 10.1186/s13045-018-0601-9

M3 - Review article

C2 - 29685160

AN - SCOPUS:85045922333

VL - 11

JO - Journal of Hematology and Oncology

JF - Journal of Hematology and Oncology

SN - 1756-8722

IS - 1

M1 - 57

ER -